
IGF-1 LR3
Dosage1mg
Rp 2.490.000per vial
Cold-chain delivery to your door around Bali. Pens and bacteriostatic water available, just ask.
- Class
- Synthetic IGF-1 analog
- Half-life
- Unknown in humans (20 to 30 hour claim is a myth; clears rapidly in rodents)
Also known as Insulin-like Growth Factor 1 Long R3, LR3
Promising in lab and animal research, not yet proven in human trials. Widely used and reported within the community.
No human clinical trials exist for IGF-1 LR3. Evidence is based on rodent models and community practice. Native IGF-1 (Mecasermin) has regulatory approval.
About this peptide
IGF-1 LR3 is native IGF-1 re-engineered to last far longer: an added 13-amino-acid extension plus an arginine substitution at position 3 let it slip past the binding proteins that would normally grab IGF-1 and switch it off, so it stays active much longer. The bodybuilding world runs it for muscle fullness and recovery, and the hands-on know-how is solid even where formal human science does not exist. Supplied as a freeze-dried powder for research use.
What it does
It switches on the body's main muscle-growth pathway, which in practice means fuller muscles, faster recovery and hard vascularity. It is one of the few compounds besides growth hormone itself genuinely geared at muscle growth. One myth to kill: injecting it into a specific muscle does not grow that muscle, it acts systemically wherever you put the needle.
What to expect
Week 1
Hard pumps and vascularity in the gym, going on community reports.
Weeks 2-4
Noticeably fuller muscles and better recovery.
Weeks 4-12
Growth continues, and this is where tissue overgrowth and low blood sugar need real watching.
Long term
There is no long-term human data. What we do know is that high IGF-1 lines up with higher cancer rates in observational studies.
A rough guide drawn from research and community reports. Individual results vary and nothing here is a promise.
Reported effects
Reported benefits
Side effects & cautions
Key points
Best suited to experienced bodybuilders and athletes after systemic muscle growth and recovery, including those who do not tolerate high growth-hormone doses. Worth being clear-eyed: the dominant acute risk is low blood sugar, and past or active cancer rules it out.
Normally binding proteins keep native IGF-1 on a short leash. LR3 dodges them, so it stays free to hit the IGF-1 receptor and drive growth signalling for longer. Worth correcting head-on: the famous 20 to 30 hour half-life is a myth with no human data behind it. In rodents LR3 actually clears up to eleven times faster than native IGF-1, precisely because it skips that binding-protein protection.
The one to respect is low blood sugar. It is the dominant acute risk, reported in 42 percent of children on native IGF-1, and a bad drop can mean seizures or passing out. Longer term, the same growth signalling can drive acromegaly-style tissue and organ overgrowth, raised pressure in the skull, and worsening diabetic eye disease. High circulating IGF-1 also tracks with modestly higher rates of prostate, breast and colorectal cancer, so active or past cancer rules it out completely.
Supplied as a freeze-dried powder for research use. Store in a cool environment and do not freeze. It can be reconstituted with bacteriostatic water to maintain sterility without denaturing the peptide. Preloaded insulin syringes should be kept on a cold pack or refrigerated. Administration in community practice is subcutaneous. Intravenous use is contraindicated and never recommended.
- Blood sugar
- Significant reduction (hypoglycemia)
What studies and users commonly report happening to these markers. Research context only, not medical advice.
Questions about IGF-1 LR3
No. Site-specific growth from LR3 is a myth. Its effects are systemic, meaning it acts throughout the body regardless of where you inject.
No. There is no human data behind the 20 to 30 hour figure. In rodent studies LR3 actually clears up to eleven times faster than native IGF-1, because it escapes the binding proteins that would normally protect it.
Increlex is FDA-approved native human IGF-1. Practitioner experience suggests Increlex is significantly more potent for muscle growth than research-grade LR3, which lacks human clinical validation.
Low blood sugar is the dominant acute risk. It can be severe and it stacks if combined with insulin or other glucose-lowering agents.
Evidence
Sourcing
Sourced carefully from vetted suppliers. Where a Certificate of Analysis is available we share it on request, and we'll always tell you what we have for your batch.
For Research Use Only
Sold strictly for laboratory and research purposes. Not for human or veterinary use, not a medicine, and not for diagnostic or therapeutic application.
Growth Hormone

HGH
10IU